Drug Profile
Eragidomide - Celgene Corporation
Alternative Names: CC-90009; GSPT1 CELMoDLatest Information Update: 03 Aug 2022
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Class Acetamides; Antineoplastics; Chlorobenzenes; Fluorine compounds; Isoindoles; Piperidines; Small molecules
- Mechanism of Action CRBN protein modulators; Peptide-chain-release factor 3 modulators; Ubiquitin protein ligase complex modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia
- Phase I Myelodysplastic syndromes
Most Recent Events
- 28 Jul 2022 Eragidomide is still in Myelodysplastic syndromes (Second-line therapy or greater) in Canada, France, Norway, Spain, United Kingdom and USA (IV) (NCT02848001)
- 28 Jul 2022 Eragidomide is still in phase I trials for Acute myeloid leukaemia (Second-line therapy or greater) in Canada, France, Norway, Spain, United Kingdom and USA (IV) (NCT02848001)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in Canada (IV)